Evidence map›Paper›PMID 35416695›Full record

ArticleMicrobiology spectrum2022

Dai Kurihara, Satoru Matsumoto, Naoko Kishi, Yoshikazu Ishii, Masahiko Mori

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Biomedicines · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dai KuriharaJapan Development, MSD K.K., Tokyo, Japan.ORCID 0000-0002-0319-3958
Satoru MatsumotoMicrobiological Testing Group, Infectious Diseases Testing Department, Clinical Laboratory Center, Medical Solution Segment, LSI Medience Corporation, Tokyo, Japan.
Naoko KishiMicrobiological Testing Group, Infectious Diseases Testing Department, Clinical Laboratory Center, Medical Solution Segment, LSI Medience Corporation, Tokyo, Japan.
Yoshikazu IshiiDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.ORCID 0000-0002-1943-4648
Masahiko MoriJapan Development, MSD K.K., Tokyo, Japan.
MSD K.K. (Japan) · JPToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relebactam is a novel β-lactamase inhibitor of Ambler class A and C β-lactamases that has been developed in combination with imipenem/cilastatin for the treatment of carbapenem-resistant bacterial infections. In this study, we evaluated the

Indexed as

AmikacinImipenemAnti-Bacterial AgentsAzabicyclo CompoundsCarbapenemsJapanMicrobial Sensitivity TestsPseudomonas aeruginosaAmikacinAnti-Bacterial AgentsAzabicyclo CompoundsCarbapenemsImipenemrelebactamcarbapenem-resistantimipenemrelebactamsusceptibility

Identifiers

PMID35416695
PMCPMC9045147
OpenAlexW4223581710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.